Skip to content

Anika Therapeutics ANIK IT — PP&E (Net)

Other geography segments

US
$37.96M
GB
$29K

Similar metrics at other companies

Euronet Worldwide logo
EEFTIT — PP&E (Net)
$10.9M-2.7%
Orthofix Medical Inc. logo
OFIXIT — PP&E (Net)
$9.6M+0.9%
Kyndryl Holdings logo
KDUS — PP&E (Net)
$877M-0.7%
Euronet Worldwide logo
EEFTIN — PP&E (Net)
$21.7M-8.8%
Impinj, Inc. logo
PITW — PP&E (Net)
$24.91M+21.3%
Opko Health logo
OPKUS — PP&E (Net)
$20.28M-24.0%

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Anika Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's it — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's IT — PP&E (net)?
Anika Therapeutics (ANIK) reported IT — PP&E (net) of $853K in Q4 2025.
How has Anika Therapeutics's IT — PP&E (net) changed year-over-year?
Anika Therapeutics's IT — PP&E (net) decreased by 14.8% year-over-year, from $1M to $853K.
What does IT — PP&E (net) mean?
This metric represents the net book value of tangible long-term assets, such as manufacturing facilities, machinery, and laboratory equipment, specifically allocated to the IT geographic or operational segment. It reflects the capital intensity and infrastructure investment required to support the company's orthopedic product development and production capabilities within this specific region. Monitoring this value helps investors assess the scale of physical operations and the ongoing maintenance or expansion requirements necessary to sustain the segment's market position.